Medicine's Default Patient Is Male, and Women Pay for It
Health·October 25, 2026
Ella Hubber set out to find a treatment for type 1 diabetes. Her early experiments used only male mice, a common choice that rarely raises eyebrows in a lab. It was only when she looked closer that she saw the omission was not confined to one project. It reflected a pattern across medicine, and she teamed up with journalist Chhavi Sachdev to follow that thread through decades of clinical research.
For much of the twentieth century, women were routinely left out of clinical trials. Concerns about pregnancy and the risk to a developing fetus led many regulators and researchers to exclude women of childbearing age, and the assumption that men could stand in for everyone became standard practice. Many medicines reached the market with evidence drawn mostly from male bodies, and those gaps were often never filled once the drugs were in use.
The problem is not only one of fairness. Biological differences between women and men, in body composition, hormones, and how the liver and kidneys process drugs, can change how a medicine behaves. Those differences help explain why women report higher rates of some side effects from certain drugs. When doses are set using mostly male data, women can end up with too much of a drug or with an effect that was never properly studied.
The program argues that the fix is practical as well as principled. Experts point to trials that recruit participants who better reflect the people who will actually take the drugs, to results reported by sex so that differences are visible, and to pharmaceutical companies being held accountable for the holes in their evidence. Hubber and Sachdev frame the question as a simple one: whether medicine is built for everyone, or only for a default patient who is male.
Reporting based on an external source.